Ocuphire Pharma Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
IRD$4.20+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| For the Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating activities | ||
| Net (loss) income | $(9,986) | $17,888 |
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ||
| Stock-based compensation | 3,510 | 1,807 |
| Depreciation | 6 | 4 |
| Fair value change in derivative liabilities | (80) | — |
| Financing costs | 1,328 | — |
| Unrealized loss from short-term investments | 34 | 170 |
| Change in assets and liabilities: | ||
| Accounts receivable | 372 | (1,298) |
| Contract assets and unbilled receivables | 2,145 | (3,552) |
| Prepaid expenses and other assets | 354 | (139) |
| Accounts payable | 1,082 | (515) |
| Accrued expenses | 123 | (51) |
| Net cash (used in) provided by operating activities | (1,112) | 14,314 |
| Investing activities | ||
| Transaction costs in connection with asset acquisition | — | — |
| Net cash used in investing activities | — | — |
| Financing activities | ||
| Proceeds from issuance of common stock | 9,227 | 4,428 |
| Issuance costs attributed to common stock | (278) | (131) |
| Payments made on short-term loan principal | — | (538) |
| Exercise of stock options and Series B warrants | 30 | 27 |
| Net cash provided by financing activities | 8,979 | 3,786 |
| Net increase in cash and cash equivalents | 7,867 | 18,100 |
| Cash and cash equivalents at beginning of period | 42,634 | 24,534 |
| Cash and cash equivalents at end of period | $50,501 | $42,634 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for income taxes | $344 | $— |
| Cash paid for interest | $— | $9 |
| Supplemental non-cash financing transactions: | ||
| Non-cash issuance of common stock in connection with equity purchase agreement | $1,022 | $— |
| Value of derivative established in connection with the equity purchase agreement | $154 | $— |
| Unpaid issuance costs | $10 | $2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.